FORCES Tavern: We welcome you to The Tavern, you are welcome to browse and read, but please register to post.

Investigation: the government/Gardasil partnership

Introduction to Immunity and Vaccination

Investigation: the government/Gardasil partnership

Postby jsidney » Wed Apr 27, 2011 12:59 am

http://www.ageofautism.com/2010/05/a-li ... rtner.html

"A License to Kill? Part 1; How A Public-Private Partnership Made the Government Merck's Gardasil Partner"

The US Department of Health and Human Services (DHHS) promotes, protects and profits from Merck's Gardasil. As Merck has generated billions in Gardasil revenue, DHHS has received millions in Gardasil profits. This 3 part investigative series gives us a look at how and why DHHS has failed to protect the medical consumer to Merck's benefit. It includes detailed critiques of the flawed clinical trials which have resulted in the promotion and sale of a vaccine which can paralyze and kill.

Read this series, even if you aren't a sexually active young woman who might risk the side effects of Gardasil. Gardasil isn't the only Big Pharma drug the DHHS has a similar vested interest in.

Background to the Merck-DHHS partnership;

The US Department of Health and Human services (DHHS) oversees the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC).

As the world's largest single sponsor of biological research, the National Institutes of Health (NIH) frequently funds research with commercially valuable outcomes. When that R&D generates potentially valuable inventions, NIH submits patent applications to the U.S. Patent and Trademark Office and actively pursues the approval of those patents, which when granted become valuable commercial property for DHHS, the patents' owner. Since NIH has neither the authority nor the capability to pursue product commercialization efforts, in order to encourage private companies to invest in conducting the necessary clinical trials, NIH grants commercial licenses for such DHHS patents to commercial partners, including vaccine manufacturers.

When new products invented at NIH clear the requisite regulatory hurdles at the FDA and reach the market, NIH then shares in the profits. They also distribute the rewards back to the scientific teams whose products have succeeded in reaching the commercial stage: when license fees flow into NIH's coffers, the Federal employees who invented the technology are entitled by NIH to a share of the royalties.

Fair enough, but when technology licensing takes place WITHIN federal agencies we have a web of conflict, one in which the same departments that are tasked with regulating the health and safety of medical products are also profiting from them.
jsidney
 
Posts: 77
Joined: Mon Dec 01, 2008 11:35 pm
Location: La Mesa CA

Return to Vaccines

Who is online

Users browsing this forum: No registered users and 3 guests

cron